CA3148956A1 - Anti-cd47 monoclonal antibody and use thereof - Google Patents

Anti-cd47 monoclonal antibody and use thereof Download PDF

Info

Publication number
CA3148956A1
CA3148956A1 CA3148956A CA3148956A CA3148956A1 CA 3148956 A1 CA3148956 A1 CA 3148956A1 CA 3148956 A CA3148956 A CA 3148956A CA 3148956 A CA3148956 A CA 3148956A CA 3148956 A1 CA3148956 A1 CA 3148956A1
Authority
CA
Canada
Prior art keywords
amino acid
seq
set forth
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3148956A
Other languages
English (en)
French (fr)
Inventor
Peng Zhang
Baiyong Li
Yu Xia
Zhongmin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of CA3148956A1 publication Critical patent/CA3148956A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3148956A 2019-09-03 2020-09-03 Anti-cd47 monoclonal antibody and use thereof Pending CA3148956A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910836601.9 2019-09-03
CN201910835819.2 2019-09-03
CN201910835819 2019-09-03
CN201910836601 2019-09-03
PCT/CN2020/113287 WO2021043220A1 (zh) 2019-09-03 2020-09-03 抗cd47的单克隆抗体及其用途

Publications (1)

Publication Number Publication Date
CA3148956A1 true CA3148956A1 (en) 2021-03-11

Family

ID=74736180

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3148956A Pending CA3148956A1 (en) 2019-09-03 2020-09-03 Anti-cd47 monoclonal antibody and use thereof

Country Status (13)

Country Link
US (1) US20220324971A1 (enExample)
EP (1) EP4026847A4 (enExample)
JP (2) JP7808546B2 (enExample)
KR (1) KR20220053665A (enExample)
CN (1) CN112442123B (enExample)
AU (1) AU2020342192A1 (enExample)
BR (1) BR112022003868A2 (enExample)
CA (1) CA3148956A1 (enExample)
IL (1) IL291049A (enExample)
MX (1) MX2022002505A (enExample)
PH (1) PH12022550489A1 (enExample)
WO (1) WO2021043220A1 (enExample)
ZA (1) ZA202203622B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024515396A (ja) * 2021-04-14 2024-04-10 中山康方生物医▲藥▼有限公司 抗ｃｄ４７モノクローナル抗体及びその使用
WO2023191117A1 (ko) * 2022-03-28 2023-10-05 (주)이노베이션바이오 친화도가 성숙된 cd47에 특이적인 인간화 항체
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
CN120714022A (zh) * 2024-03-27 2025-09-30 康方汇科(上海)生物有限公司 药物组合及用途
WO2026051964A1 (en) * 2024-09-04 2026-03-12 Akeso Biopharma Co., Ltd. Antibody that binds vegfa and pd-1 and uses thereof to treat cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP4349868A3 (en) 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
RU2015122228A (ru) * 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
HK1257309A1 (zh) * 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法
ES2796378T3 (es) * 2016-01-11 2020-11-26 Forty Seven Inc Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos
KR102607101B1 (ko) 2017-01-26 2023-11-29 제트엘아이피 홀딩 리미티드 Cd47 항원 결합 유닛 및 그것의 사용
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
US20220298254A1 (en) 2017-11-01 2022-09-22 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
AU2019212674A1 (en) 2018-01-24 2020-09-03 Nanjing Legend Biotech Co., Ltd. Anti-CD47 antibodies that do not cause significant red blood cell agglutination
CN109265547B (zh) 2018-07-23 2022-07-26 中国科学院微生物研究所 一种抗cd47抗体及其应用
CN109438576B (zh) * 2018-11-14 2021-08-20 上海交通大学 一种抗人cd47单克隆抗体的制备及其应用
CN118459587A (zh) * 2019-02-01 2024-08-09 启晨佰泰(北京)医药科技有限公司 抗cd47抗体及其应用

Also Published As

Publication number Publication date
EP4026847A4 (en) 2024-01-10
CN112442123B (zh) 2022-08-23
EP4026847A1 (en) 2022-07-13
KR20220053665A (ko) 2022-04-29
CN112442123A (zh) 2021-03-05
ZA202203622B (en) 2024-01-31
IL291049A (en) 2022-05-01
JP2025114620A (ja) 2025-08-05
JP2022545974A (ja) 2022-11-01
JP7808546B2 (ja) 2026-01-29
BR112022003868A2 (pt) 2022-05-31
AU2020342192A1 (en) 2022-04-21
PH12022550489A1 (en) 2022-12-12
MX2022002505A (es) 2022-06-02
WO2021043220A1 (zh) 2021-03-11
US20220324971A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US12479919B2 (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
AU2019412405B2 (en) Antibody against human IL-4RA and use thereof
US11555077B2 (en) 4-1BB antibody and preparation method and use thereof
CN110382536B (zh) 抗pd-1抗体及其用途
JP7808546B2 (ja) 抗ｃｄ４７モノクローナル抗体及びその使用
CN112574310A (zh) 抗SIRPα抗体及其用途
JP7538131B2 (ja) 抗ｃｄ７９ｂ抗体、その抗原結合フラグメントおよびそれらの医薬用途
IL305363A (en) Anti-cd47 monoclonal antibody and use thereof
CN114437227A (zh) 双特异抗体及其应用
CN119403833A (zh) 分离的抗原结合蛋白及其用途
CN114656566B (zh) 一种靶向cd47的抗体及其应用
KR20220050182A (ko) 항-cd22 항체 및 그의 용도
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
HK40076698A (en) Anti-cd47 monoclonal antibody and use thereof
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
EA051039B1 (ru) Анти-cd47 моноклональное антитело и его применение
EP4446341A1 (en) Antibody binding to bcma and use thereof
KR20260047587A (ko) 항-ox40l 항체 및 이의 용도
HK40073393A (en) Bispecific antibody and use thereof
KR20230169942A (ko) 항-pd-l1 항체 및 이의 용도
HK40119369A (zh) 抗SIRP α抗体及其用途
HK40076375B (zh) 抗SIRPα抗体及其用途
EA051797B1 (ru) Антитело против человеческого il-4ra и его применение
HK40011027A (en) Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240729

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241101

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241115

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250804

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260121